Noile-Immune Biotech, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Noile-Immune Biotech, Inc.
While the SVB and wider banking crisis has shaken VCs and bioventures in the US and Europe, Japan has mixed view on its impact and the government is keeping an eye on the situation. But one biotech has nevertheless cautiously decided to withdraw from a market listing despite Tokyo Exchange Market approval.
With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.
Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.
- Gene Therapy, Cell Therapy
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.